Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review

Divya RSJB Rana, MS[1] & Santosh Dulal, MS, PhD[1, 2]*

[1]Center for Applied and Allied Sciences, Kathmandu, Nepal

[2]Department of Biotechnology, National College, Tribhuvan University, Kathmandu, Nepal

*Corresponding author: drsantoshdulal@gmail.com

Abstract:

The corona virus disease -2019 (COVID-19) pandemic has caused a massive global public health havoc. Recent published clinical trials show conflicting data for use of chloroquine/hydroxychloroquine for COVID-19. This study meticulously evaluated the various dosages of chloroquine and hydroxychloroquine utilized in clinical trials registered in Chinese and US clinical trial registries for the treatment of pneumonia caused by SARS-CoV-2. Moreover, the results of published clinical trials and *in vitro* studies using chloroquine and hydroxychloroquine relevant to the disease are discussed.

Background

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease of potential zoonotic origin (1). Severe acute respiratory syndrome (SARS) corona virus – 2, (SARS-CoV-2), the etiological agent of COVID-19, can cause a serious or life-threatening disease or condition, including severe respiratory illness (1). The public health concerns caused by the outbreak of COVID-19 was declared as a “public health emergency of international concern” on 31 January and “pandemic on 11 March 2020 by World Health Organization (2). Impacts of the COVID-19 pandemic are currently ‘skyrocketing’ across the globe, causing enormous public health havoc and a colossal economic crisis. The spread of COVID-19 is so accelerating that it needed sixty seven days from the first diagnosed case to reach the first 100,000 cases, eleven days for the second 100,000 cases, four days for the third 100,000 cases, three days for the fourth 100,000 cases and just extra seven days for additional 400,000 cases around the globe. A similar pattern has been seen in the fatality as it required seventeen days from the first death reported on 11 January 2020 to reach the first 100 deaths, thirty days for the 1,000 deaths, sixty one days for the 5,000 deaths and sixty eight days for 10,000 deaths and just nine additional days for additional 20,000 deaths. By 1 April 2020, the number of confirmed cases skyrocketed to approximately 823,000 and 40,598 deaths from 205 countries and territories around the globe (3). In the single day of 31 March, there were approximately 72,700 new confirmed cases and 4,193 deaths reported across the world (3). The reported mortality rate for COVID-19 is around 3% (4) and the mortality rates vary depending on geographical regions, age distributions and co-morbidities (5). Recently, the Chinese Government included chloroquine phosphate in the list of antiviral therapies for the treatment of novel coronavirus pneumonia or COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in its 6th and 7th versions of official Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia caused by COVID-19 (6,7). Immediate research on the potential therapeutic application for the disease can

save lives and prevent from the rapid viral transmission. Chloroquine phosphate is an old drug used for the treatment of malaria caused by *Plasmodium species (8)*. Chloroquine phosphate can also be replaced with another member of its family, hydroxychloroquine. The active compound chloroquine constitutes 60% in chloroquine phosphate and 77.5% in hydroxychloroquine respectively.

Mechanism of actions of chloroquine or hydroxychloroquine has been studied for both SARS-CoV and SARS-C0V-2. A study using Vero E6 cells found that treatment of the cells with chloroquine either before or after infection with SARS-CoV could prevent infection or treat the infected cells suggesting both prophylactic and therapeutic effect (8). The study found chloroquine disturbed the biochemical maturation of the cellular receptor, angiotensin converting enzyme 2 (ACE2), for SARS-CoV, and increased the pH of intracellular virus-laden vesicles inhibiting the viral normal multiplication processes. The receptor for SARS-CoV-2 is also highly predicted of being ACE2 (1). In vitro studies for SARS-CoV-2 also found chloroquine and hydroxychloroquine, a less-toxic derivative of chloroquine to be able to effectively inhibit viral growth (9). They found the viral biological processes in the endosomes were affected by the anti-malarial agents. While the reported 50% effective concentration of the drugs are higher than the normal serum concentration reported in people taking these drugs, the concentrations in lungs and other vital organs are higher (10). The most common side-effect of these are retinopathy and other side-effects precipitating due to higher concentrations of the compounds in blood.

The recommended 3-day chloroquine phosphate dosage for malaria treatments for adults is 1 gm orally followed by 500 mg after 6-8 hours in the first day and 500 mg per day for second and the third day (8). Similarly, the 3-day dosage for hydroxychloroquine is 800 mg orally followed by 400 mg after 6-8 hours in the first day and 400 mg per day for second and third day (11). This study was specifically conducted to examine the various dosages of chloroquine and hydroxychloroquine utilized in previous clinical trials registered and underwent for the treatment of pneumonia caused by SARS-CoV-2. The guidelines by the Chinese government has postulated the dose of 500 mg twice a day for 7 days for adults aged 18-65 years and weighing more than 50 kg; and initial dose of 500 mg twice a day for first two days and 500 mg per day for days 3 through 7 for adults of weight less than 50 kg (7).

Methods:

A systematic search of registered clinical trials was carried (Figure 1, PRISMA flow-chart). List of clinical trials registered in China were utilized in this study accessing with a ready-made excel spreadsheet from the Chinese clinical trial registry (12), on 30th March, 2020 provided in the website. The list of clinical trials registered in the US government clinical trial registry (13) were retrieved by searching “coronavirus” key word on 30th March, 2020. All the trials were filtered out based on the presence of word “chloroquine” in the title irrespective of the chemical forms of the molecule (hydroxychloroquine) or trials being carried alone or in combination with other antivira therapies. Excel spreadsheet file was prepared based on various headings including intervention groups, randomization status, sample sizes, etc. Univariate statistics were used to report the methodologies of the trials. As of 30th March 2020, 547 trials were registered in the Chinese clinical trial registry starting from 23rd January, 2020. 25 (4.6%, 25/547) clinical trials used the word chloroquine in their titles. Five of them were reported to have been canceled, one was a prophylactic study and one another could not be retrieved. Eighteen (3.3%, 18/547) clinical trials from the Chinese registry were used for the downstream analysis. As of 30th March 2020, 184 entries were obtained by searching for coronavirus related clinical trials in the US clinical trial registry of which only 153 were registered after 1 January 2020. Out of 153 registrations, 20 (13.1%, 20/153) were related to use of chloroquine. Four of these were registered from China, 3 from Brazil, 2 each from France, Mexico, US

and Canada, and 1 each from Thailand, South Korea, United Kingdom, Norway and Turkey. Two of the studies from US, and 1 each from the United Kingdom, Mexico and Turkey were prophylactic study for healthy people at risk of infection. Thus 15 studies from US trial registry were used for analysis. Total 33 (18+15) clinical trials have been registered since 3rd February 2020. Six prophylactic studies were analyzed separately.

Table 1: Use of different forms of chloroquine in clinical trials

Type of trials	**Trials (%)***
Chloroquine phosphate**	15 (68.2%)
Chloroquine phosphate with other antivirals	3 (13.6%)
Chloroquine with azithromycin	1 (4.5%)
Hydroxychloroquine	15 (68.2%)
Hydroxychloroquine with others	1 (4.5%)
Hydroxychloroquine with azithromycin	2 (9.1%)
Chloroquine phosphate as aerosol inhalation	2 (9.1%)
Total	33 (100%)

*Few trials have one or more types together in same study

Table 2: Dosages and characteristics of the registered clinical trials

Trial No.	Arms in Trial	Treatment Dosage* (Only CQ and HCQ arms discussed)	Placebo/ Standard care arm presence	Randomization	Country	Results Published
ChiCTR2000029542	2	CQ: 500 mg, BD, 7 days Placebo/Standard care	Yes	N0	China	No
ChiCTR2000029559	3	HCQ: 100 mg, BD HCQ: 200 mg BD Placebo/Standard Care	Yes	Yes	China	Yes

ChiCTR2000029609	3	CQ: 250 mg CQ+antiviral: 250 mg Antiviral	No	No	China	No
ChiCTR2000029741	2	CQ: NA Antiviral	No	No	China	No
ChiCTR2000029826	2	CQ: 2 tabs, BD Placebo/Standard Care	Yes	Yes	China	No
ChiCTR2000029837	2	CQ: 2 tabs, BD Placebo/Standard Care	Yes	Yes	China	No
ChiCTR2000029868	2	HCQ: D1-3: 400 mg, TDS; D4-14: 400 mg BD Placebo/Standard Care	Yes	Yes	China	No
ChiCTR2000029898	2	CQ: D1-3: 500 mg, BD; D4-5: 250 mg, BD HCQ: D1: 600 mg BD, D2-5: 200 mg, BD	No	Yes	China	No
ChiCTR2000029935	1	CQ: NA	No	Single Arm	China	No
ChiCTR2000029939	2	CQ: NA Placebo/Standard care	Yes	Yes	China	No
ChiCTR2000029975	1	CQ: 150 mg aerosolized, q12h, 7 days	No	Single Arm	China	No
ChiCTR2000029988	2	CQ: NA Placebo/Standard Care	Yes	Yes	China	No
ChiCTR2000029992	3	CQ: D1-2: 500 mg BD; D3-14: 250 mg, BD HCQ: 200 mg, BD, 14 days Placebo/Standard care	Yes	Yes	China	No
ChiCTR2000030054	3	CQ: D1-2: 500 mg BD; D3-14: 250 mg, BD HCQ: 200 mg, BD, 14 days Placebo/Standard care	Yes	Yes	China	No
ChiCTR2000030417	2	CQ: aerosols Placebo/Standard care	Yes	Yes	China	No

ChiCTR2000030718	2	CQ: NA Placebo/Standard Care	Yes	Yes	China	No
NCT04303299	8	HCQ: Arm 1: 800 mg/day, 10 days with different antivirals; Arm2, 6, 7: 400 mg/day, 10 days with different antivirals Placebo/Standard care	Yes	Yes	Thailand	No
NCT04261517	2	HCQ: 400 mg/day, 5 days Placebo/Standard care	Yes	Yes	China	**Yes**
NCT04286503	4	CQ: NA	No	Yes	China	No
NCT04307693	3	HCQ: 200 mg, BD, 7-10 days Placebo/Standard care	Yes	Yes	South Korea	No
ChiCTR2000030987	3	CQ: NA, with antivirals Placebo/Standard care	Yes	Yes	China	No
ChiCTR2000031204	2	CQ: NA Placebo/Standard care	Yes	Yes	China	No
NCT04316377	2	HCQ: 400 mg, BD, 7 days Placebo/Standard care	Yes	Yes	Norway	No
NCT04315948	5	HCQ: D1: 400 mg, BD; D2-10: 200 mg OD Placebo/Standard care	Yes	Yes	France	No
NCT04315896	2	HCQ: 200 mg, BD, 10 days Placebo/Standard care	Yes	Yes	Mexico	No
NCT04319900	3	CQ: D1: 500 mg, BD; D2-3: 500 mg, OD; D4-10: 250 mg, OD; all with other antivirals Placebo/Standard care	Yes	Yes	China	No
NCT04321278	2	HCQ: Arm 1: 400 mg, BD, 10 days, with azithromycin; Arm 2: 400 mg, BD, 10 days;	No	Yes	Brazil	No
NCT04321616	3	HCQ: D1: 600 mg, BD; D2-10: 300 mg, TDS Placebo/Standard care	Yes	Yes	Norway	No
NCT04321993	4	HCQ: 400 mg, BD, 10 days	No	No	Canada	No

NCT04322123	3	HCQ: Arm 1: 400 mg, BD, 7 days; Arm 2: 400 mg, BD, 7 days with azithromycin Placebo/Standard care	Yes	Yes	Brazil	No
NCT04323527	2	CQ: Arm 1 (low dose): D1: 450 mg, BD; D2-5: 450 mg, OD; Arm 2 (high dose): 600 mg, BD, 10 days	No	Yes	Brazil	No
NCT04324463	2	CQ: Body wt. >50 kg: 500 mg, BD, 7 days; Body wt. <50 kg: D1-2: 500 mg, BD; D3-7: 500 mg, OD; both groups with azithromycin Placebo/Standard care	Yes	Yes	Canada	No
NCT04325893	2	HCQ: D1: 400 mg, BD; D2-8: 200 mg, BD Placebo/Standard care	Yes	Yes	France	No

*CQ, chloroquine; HCQ, hydroxychloroquine; Not all studies provided all the details of dosages

Table 3: Dosages and characteristics of prophylactic clinical trials

Trial No.	Arms in Trial	Treatment Dosage* (Only CQ and HCQ arms discussed)	Placebo/ Standard care arm presence	Randomization	Country	Results Published
ChiCTR2000029803	4	HCQ: High dose; Low dose	No	Yes	China	No
NCT04303507	2	CQ: D1: 10 mg/day; 250 mg, OD, 3 months Placebo	Yes	Yes	UK	No
NCT04308668	2	HCQ: D1: 800 mg followed by 600 mg after 6-8 hrs; 600 mg, OD, 4 days Placebo	Yes	Yes	US	No
NCT04318015	4	HCQ: High-risk group: 200 mg, OD, 60 days; Low-risk group: 200 mg, OD, 60 days Placebo: High-risk and Low-risk group both placebo	Yes	Yes	Mexico	No

NCT04318444	2	HCQ: D1: 400 mg, BD; D2-5: 200 mg, BD Placebo	Yes	Yes	US	No
NCT04326725	1	HCQ: 200 mg, once in three weeks, with daily vitamin C and zinc tabs	Yes	No	Turkey	No

*CQ, chloroquine; HCQ, hydroxychloroquine; Not all studies provided all the details of dosages

Results:

Most of the trials used oral chloroquine (68.2%, 15/33) or hydroxychloroquine (68.2%, 15/33) singly as treatment options, followed by chloroquine in combination with other antivirals ((13.6%, 3/33), hydroxychloroquine with azithromycin (9.1%, 2/33), chloroquine as aerosols (9.1%, 2/33), chloroquine with azithromycin (4.5%, 1/33) and hydroxychloroquine with other antivirals (4.5%, 1/33) (Table 1). The maximum quantity of chloroquine given was 12 g in a period of 10 days (NCT04323527) and the lowest reported was 2.1 g aerosolized chloroquine (ChiCTR2000029975) in a duration on 7 days. Similarly, the maximum quantity of hydroxychloroquine given was 12.4 gm in a duration of 14 days (ChiCTR2000029868) and the lowest amount was 2 gm in a period of 5 days (NCT04261517). Only one of the two trials using aerosolized chloroquine phosphate stated the dosage. It was 2.1 gm in a period of 7 days (ChiCTR2000029975). All 12894 study patients are planned to be enrolled in 33 trials. Twelve trials registered in the US registry didn't have details about sample size allocation into individual intervention arms. For the remaining 5842 individuals in 21 trials with information of sample sizes, 1199 patients are to get chloroquine alone, 1050 are to get hydroxychloroquine alone 159 got chloroquine with other drugs, 25 are to get aerosolized chloroquines, 1320 are to get conventional treatments or placebo, and 2089 are to get other antivirals. All of the active or placebo interventions also get conventional treatments or the standard care. Out of the 33 clinical trials, 4 reported that they were not designed to be randomized, two were single arm studies and didn't require randomization and 27 reported using some kind of randomization. Out of total, three-fourth (91%, 30/33) studies set 18 years old as lower age limit for inclusion criteria while two trials used 16 years, and one trial used 30 years. Similarly, upper age limit ranged from 65 to 100 years of age. All trials reported enrolling both genders in the study.

Among the trials using chloroquine or hydroxychloroquine as prophylactic agent (Table 3), 45400 healthy at-risk population are to be enrolled with the UK study by the University of Oxford, enrolling 40,000 individuals for a duration of three months with 250 mg chloroquine daily (NCT04303507) and the least dose is planned to be given in a study in Turkey where 200 mg hydroxychloroquine is planned to be given every three weeks along with daily vitamin C and zinc tablets) (NCT04326725). The results of these trials, if successful, can provide low-cost option for vaccination which may require more than a year to be available in the developing world.

Two trials from China have recently published their results (NCT04261517 and ChiCTR2000029559). The background information in a Chinese clinical trial (ChiCTR2000029741) (14) has revealed that fifty percent (5/10) efficacy of chloroquine phosphate (5 days medications) in COVID-19 compared to 20% (3/15) efficacy of combinatory medications of lopinavir/ritonavir (5 days medications) in Chinese pneumonia patients in 2020.

The Chinese government in its 6th and 7th guidelines for the treatment of novel coronavirus pneumonia has recommended use of chloroquine phosphate at specific dosages (Table 3). Three studies (including two mentioned earlier) have been published that assessed the efficacy of

hydroxychloroquine in COVID-19 patients. A non-randomized open-label clinical trial in France that enrolled hospitalized COVID-19 patients to the hydroxychloroquine (20 patients) and control arms (16 patients) concluded a positive effect of hydroxychloroquine or hydroxychloroquine plus azithromycin based on viral negativity at day 6 (15). Patients who didn't consent for hydroxychloroquine, had exclusion criteria (allergy to hydroxychloroquine, retinopathy, G6PD deficiency, QT prolongation and breast feeding/pregnacy) and were admitted to hospitals not using hydroxychloroquine, were grouped in the controlled arm. Six patients in the case arm also received azithromycin to prevent bacterial superinfection. Though the study had small sample size, was not randomized and didn't carry an intention-to-treat analysis, it concluded positive effects for hydroxychloroquine arm in spite of lesser proportion of "asymptomatic" patients (10% in hydroxychloroquine arm vs. 25% in control arm) and higher average age (51.2 years in hydroxychloroquine arm vs 37.3 years in control arm) in the intervention arm. Moreover, a secondary analysis (16) covering up for the weak statistical analyses by original authors found the azithromycin and hydroxychloroquine combination are was better compared to the control arm. Another study carried an open label randomized clinical trial in 30 Chinese COVID-19 patients treated with either hydroxychloroquine (15 patients) or conventional methods (15 patients) (17). The study concluded no apparent benefit of hydroxychloroquine treatment compared to conventional treatment (86.7% treatment arm vs 93.3% control arm had negative viral conversion on day 7, $p>0.05$). But the authors reported using interferon alfa in all of the patients and 80% patients in each arm were treated with other antiviral therapies. Moreover, the authors cautioned the high recovery rate in control arm due to enrollment of mild cases could impact the comparison of efficacy of treatment arm. The third published study (as a preprint at the time of writing this manuscript) from the Renmin Hospital of Wuhan University, Wuhan, China, (ChiCTR2000029559) claimed to find an positive effect of hydroxychloroquine in a double-blind randomized control design. 80.6% (25/31) patients in the treatment arm (400 mg hydroxychloroquine/day for 5 days) had improved pneumonia compared to 54.8% (17/31) in the control arms, along with other better outcome measures in the treatment arm (18). Patients in both of the arms were reported to have been treated with other antivirals and antibiotics. A recent review found the inclusion of chloroquine/hydroxychloroquine based therapy in the national guidelines of China, Korea, Netherlands, Italy, Canada and Belgium (19). More recently, the US Food and Drug Administration has allowed an emergency use authorization for these drugs against COVID-19 when used by a valid health care provider (20).

Discussion:

Modern and robust scientific interventions at national and international level for prevention, containment and treatment has protected mankind from various deadly diseases like Ebola, Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, etc. in the contemporary parameters. The Spanish flu about one hundred years ago claimed about up to 50 million lives (21) as modern scientific knowledge were contemporarily lacking and limited. As predicted, in the absence of these measures, if 60% of global population were infected as forecasted by experts, and approximately 20% required treatment of chloroquine phosphate or hydroxychloroquine sulphate (22), the cost could range tens of thousands USD per million population (Table 3).

Table 3: Dosages and corresponding cost estimations with respect to Indian drug prices

Medication	Recommended Dose (based on Clinical trials)	Average Drug Cost IRs (USD) based on Indian Market*	Cost for recommended doses (USD)	Cost per Predicted 1M Infection**

Chloroquine Phospahate	500 mg BD 7 days	USD 0.0148 (500 mg)	0.71	USD 12.5K
Hydroxychloroquine^	200 mg TID 10 days	USD 0.0905 (200 mg)	2.71	USD 163.1K
*Average calculated based on prices in India (23,24) **60% of 1 mil. infected and 10% of infected requiring treatment ^Reference (15), 200mg TID 10 days				

Currently, there are very limited information and knowledge regarding the therapeutic aspects of COVID-19 as most of the clinical trials are still undergoing and their findings have not publicly available yet. Touret and de Lamballerie (25) reported the scarcity of findings of clinical trials on therapeutic aspects of chloroquine or hydroxychloroquine. However, Gao et al. (26) in an abstract article revealed that chloroquine phosphate had superior efficacy for controlling the inhibition of pneumonia exacerbation, and disease progression and transmission in more than 100 Chinese COVID-19 patients. Recent and previous *in vitro* studies have shown the effectiveness of chloroquine and hydroxychloroquine against COVID-19 or other coonaviruses (Table 4). Thus more studies are warranted to confirm the efficacy and safety for use of these medications.

Table 4: In vitro studies using chloroquine/hydroxychloroquine against coronavirus. (SD)

Virus	Host	Drug	EC50* (mcM)	Author, Year
SARS-CoV-2	Vero	Hydroxychloroquine sulf.	0.72 (poi)	Yao 2020
SARS-CoV-2	Vero	Chloroquine phosp.	5.47 (poi)	Yao 2020
SARS	Vero E6	Chloroquine	4.1 (poi)	de Wilde 2014
MERS	Huh7	Chloroquine	3.0 (poi)	de Wilde 2014
HCoV-229E	Huh7	Chloroquine	3.3 (poi)	de Wilde 2014
SARS	Vero E6	Chloroquine	1 mcM (pri)_	Vincent 2005
SARS	Vero E6	Chloroquine	4.4 mcM (poi)	Vincent 2005
rHCoV-OC43	BHK-21	Chloroquine	IC50 0.33 (poi)	Shen 2016
HCoV-OC43	HRT-18	Chloroquine phosp.	0.306 mcM (poi)	Keyaerts 2009
Dendritic cell	MERS	Chloroquine diphosp.	Not effective	Cong 2018
SARS	Vero E6	Chloroquine	IC50 8.8 (poi)	Keyaerts 2004
FIPV	CRFK	Chloroquine diphosp.	IC50 16.63 (pri)	McDonagh 2014

FIPV	CRFK	Chloroquine diphosp.	IC50 0.38 (24h pri)	McDonagh 2014
FIPV	CRFK	Chloroquine diphosp.	IC50 28.87 (48h pri)	McDonagh 2014
MERS	Vero E6	Chloroquine diphosp.	6.3 (pri)	Dyall 2014
SARS	Vero E6	Chloroquine diphosp.	6.5 (pri)	Dyall 2014
MERS	Vero E6	Hydroxychloroquine sulf.	8.3 (pri)	Dyall 2014
SARS	Vero E6	Hydroxychloroquine sulf.	7.9 (pri)	Dyall 2014
SARS	Vero 76	Chloroquine	2.5 (sti)	Barnard 2006
SARS	Vero 76	Chloroquine diphosp.	6.0 (sti)	Barnard 2006
SARS-CoV-2	Vero E6	Chloroquine	1.13 (pri)	Wang 2020

*50% effective concentration unless stated; IC50: 50% inhibitory concentration; poi: post infection; pri: pre infection; sti: drug and infection at same time

**References in supplementary information

In spite of that, continued efforts to try different dosages in ethically valid clinical trials is required for the assessment of effective and safe dosage administration. This can importantly contribute to guide the medical professionals for prescribing the accurate interventions and also contribute to pharmaceutical companies for deciding appropriate manufacturing pathways. While hydroxchloroquine has low dosage requirements and lesser side effects, the comparative price for complete prescribed treatment is more than five times of chloroquine phosphate (24) . While malaria is endemic in poor parts of the world, the prevalence is still too less than the panic and feared caused by prevalence of COVID-19 prompting pharmaceuticals for scaling up for the production of chloroquine. As chloroquine has significant adverse events, effective short-course dosing is very important. Moreover, both of these drugs are prescribed for weeks to months for various indications (8,11) and the interventions for short disease course (2 weeks for mild and 3-4 weeks for severe and critical cases) (22) of COVID-19 may not significantly hamper treatment. Other antiviral drugs in pipeline may not be very useful as their productions and supplies to the developing countries may require lengthy timeframe whereas mass production of chloroquine and hydroxychloroquine is already in place in malaria endemic developing countries.

Conclusion:

Evaluating the potentially favorable benefit-risk balance, without any choice of valid therapeutic options left, chloroquine and hydroxychloroquine could be applicable for the management of COVID-19 in the present context of outbreak, however the respective national guidelines and clinician's evaluation and decision is recommended. In conclusion, chloroquine and hydroxchloroquine might have therapeutic potential for the medication of COVID-19 in the current context of pandemic situation. However, the corroborating evidences from these undergoing clinical trials are definitely demanded to make the ultimate decision on COVID-19 treatment.

Statement on funding sources: None

Conflicts of interest: None

References:

1. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar 12;579(7798):270–3.
2. WHO. WHO Director-General's opening remarks at the mission briefing on COVID-19 - 26 February 2020 [Internet]. 2020 [cited 2020 Mar 17]. p. 1–6. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
3. WHO. Coronavirus disease 2019 (COVID-19) Situation Report-72 HIGHLIGHTS [Internet]. [cited 2020 Apr 2]. Available from: www.who.int/epi-win.
4. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet [Internet]. 2020 [cited 2020 Mar 17];395:470–3. Available from: https://doi.org/10.1016/S0140-6736
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020 [cited 2020 Mar 17]; Available from: https://doi.org/10.1016/S0140-6736
6. ChinaGov. 《新型冠状病毒肺炎诊疗方案（试行第六版）》解读_解读_中国政府网 [Internet]. [cited 2020 Mar 17]. Available from: http://www.gov.cn/zhengce/2020-02/19/content_5480958.htm
7. ChinaGov. 《新型冠状病毒肺炎诊疗方案（试行第七版）》解读_解读_中国政府网 [Internet]. [cited 2020 Mar 17]. Available from: http://www.gov.cn/zhengce/2020-03/04/content_5486710.htm
8. Drugs.com. Chloroquine Dosage Guide with Precautions - Drugs.com [Internet]. [cited 2020 Mar 17]. Available from: https://www.drugs.com/dosage/chloroquine.html
9. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov [Internet]. 2020 Mar 18 [cited 2020 Apr 2];6(1):16. Available from: http://www.nature.com/articles/s41421-020-0156-0

10. Browning DJ, Browning DJ. Pharmacology of Chloroquine and Hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. Springer New York; 2014. p. 35–63.

11. Drugs.com. Hydroxychloroquine Dosage Guide with Precautions - Drugs.com [Internet]. [cited 2020 Mar 17]. Available from: https://www.drugs.com/dosage/hydroxychloroquine.html

12. ChiCTR.org.cn. Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform [Internet]. [cited 2020 Mar 17]. Available from: http://www.chictr.org.cn/enindex.aspx

13. Clinicaltrials.org. Home - ClinicalTrials.gov [Internet]. [cited 2020 Mar 17]. Available from: https://clinicaltrials.gov/

14. Xia J. 中国临床试验注册中心 - 世界卫生组织国际临床试验注册平台一级注册机构 [Internet]. [cited 2020 Mar 17]. Available from: http://www.chictr.org.cn/showproj.aspx?proj=49263

15. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 Mar 20 [cited 2020 Apr 2];105949. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32205204

16. Lover AA. Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020). medRxiv. 2020 Mar 27;2020.03.22.20040949.

17. Jun C, Danping L, Li L, Ping L, Qingnian X, Lu X, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Medical Sci. 2020 Mar 6;49(1):0–0.

18. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020 Mar 31;2020.03.22.20040758.

19. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020 May 1 [cited 2020 Apr 2];14(3):241–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1871402120300515

20 US-HHS. HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients | HHS.gov [Internet]. [cited 2020 Apr 3]. Available from: https://www.hhs.gov/about/news/2020/03/29/hhs-accepts-donations-of-medicine-to-strategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html

21. Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002 Mar;76(1):105–15.

22. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. [cited 2020 Mar 17]. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf

23. MEDLINE INDIA - CHLOROQUINE [Internet]. [cited 2020 Mar 17]. Available from: http://www.medlineindia.com/antibiotic/chloroquine.htm

24. Medline-India. MEDLINE INDIA - HYDROXYCHLOROQUINE [Internet]. [cited 2020 Mar 17]. Available from: http://www.medlineindia.com/antibiotic/hydroxychloroquine.html

25. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Vol. 177, Antiviral Research. Elsevier B.V.; 2020. p. 104762.

26. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. [cited 2020 Mar 17]; Available from: www.biosciencetrends.com

Figure 1: PRISMA work-flow for the search of clinical trials registered in Chinese and US clinical trial registries.



WPS Office
WPS Office